Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment

Treatment of Fabry disease (FD) with recombinant alpha-galactosidase A (r-αGAL A) is complicated by the formation of anti-drug antibodies in the majority of male patients with the classical disease phenotype. Detailed information regarding antibody subtypes, onset and persistence of antibody develop...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular genetics and metabolism 2019-02, Vol.126 (2), p.162-168
Hauptverfasser:	van der Veen, S.J., van Kuilenburg, A.B.P., Hollak, C.E.M., Kaijen, P.H.P., Voorberg, J., Langeveld, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	ADAs Adolescent Adult alpha-Galactosidase - immunology alpha-Galactosidase - therapeutic use Anti-drug antibodies Antibodies - classification Antibodies - immunology Enzyme replacement therapy Fabry disease Fabry Disease - drug therapy Follow-Up Studies Humans Immunoglobulin G - immunology Isoenzymes - immunology Isoenzymes - therapeutic use Lysosomal storage disease Male Middle Aged Neutralizing antibodies Recombinant Proteins - immunology Recombinant Proteins - therapeutic use Retrospective Studies Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!